This site is intended for health professionals only!

Published on 7 July 2011

Share this story:

Oxytocin positively affects Prader-Willi syndrome

teaser

Oxytocin positively affects patients by improving trust, mood, and reducing disruptive behaviour, according to Orphanet Journal of Rare Diseases.

New research published in BioMed Central’s open access journal Orphanet Journal of Rare Diseases, demonstrates that the hormone oxytocin is able to positively affect patients by improving trust, mood, and reducing disruptive behaviour.

Prader-Willi syndrome is a rare genetic disorder affecting one child in 25,000. Children born with this syndrome have a range of complex neurological and developmental problems, which continue into adult life. These can manifest as cognitive and behavioural difficulties, weight gain, problems in controlling their temper and attendant difficulties in socialisation.

Oxytocin is a key hormone in building social interactions and empathy. It has been shown that taking oxytocin can improve the ability of both healthy and autistic people to read faces and recognise emotion in others. Since Prader-Willi syndrome shares some characteristics with autism, and is also associated with a reduction in the number of oxytocin producing neurons, researchers from France enrolled people at a dedicated centre on a trial testing the use of the hormone.

Patients involved in the trial often stayed at the centre for one month visits where they took part in daily occupational and physical activities. They also received medical care and psychological support as needed. During one of their usual visits the patients received a single dose of either oxytocin, or placebo, and their eating and behaviour monitored for two days prior to the treatment, and two days after.

Professor Tauber from Centre de Référence du Syndrome de Prader-Willi, France, said, “Two days after administration of oxytocin, we noticed that our patients had increased trust, decreased sadness and showed less disruptive behaviour. Despite the small size of our trial, a single dose of oxytocin had a significant, late acting, effect on our patients. This is really encouraging news for the continued management of people with Prader-Willi syndrome.”

Orphanet Journal of Rare Diseases



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: